Skip to content

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 71% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 71% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.

Earnings season recap: the GSK share price is up, while the Tullow Oil share price tanks

The British drug maker saw its shares rally to a 17-year high after a strong third quarter, while the UK-based oil and gas company watched its stock plummet after downgrading its full-year production guidance.

London Stock Exchange Source: Bloomberg

Earnings season has delivered some highs and lows for various stocks, with GlaxoSmithKline (GSK) reaping the rewards of its joint venture with Pfizer in a move that has created a market leader in consumer healthcare and sent its shares soaring.

Meanwhile, Tullow Oil has seen its shares rocked after it was forced to downgrade its full-year (FY) production guidance due to issues at drill sites in Ghana.

GSK sees shares soar to 17-year high and could see further gains

GSK saw its share price close to a 17-year high of £17.82 after its third-quarter (Q3) results last month.

The drug maker recorded strong sales growth in the trading period, prompting it to upgrade its FY earnings forecast.

‘GSK has made further good progress in Q3, with sales growth across all three businesses, and we have today upgraded our full-year EPS guidance,’ GSK chief executive officer (CEO) Emma Walmsley said.

‘This quarter we have continued to strengthen our pipeline and have advanced assets in Respiratory, HIV and, notably, Oncology, where we are on track to file three innovative medicines by year end, following positive pivotal trial data.’

Looking to trade GSK and Tullow Oil? Open a live or demo account with IG.

Analysts remain upbeat about the prospect of the stock not only returning to record levels but breaking above them.

Analysts at DZ Bank remain the most optimistic, reiterating their ‘buy’ rating for the stock in October and issuing a target price £20 a share. Liberum Capital and Credit Suisse gave a price target of £18.90 and £18 respectively.

Based on the stock’s current price of £17.14 as of 16:00 GMT on Tuesday, the three banks believe that GSK’s share price has a potential upside of between 5% to 16.6%.

GSK will unveil its Q4 results on 5 February.

Tullow Oil sees share price tank after downgrading full-year production

Tullow Oil saw its share price plummet more than 30% last week after it downgraded its full-year production guidance.

Full-year 2019 oil production is forecast to average around 87,000 barrels of oil per day. This is slightly below previous guidance, primarily due to weaker-than-expected production performance at its operations in Ghana, with drilling suspended at its TEN fields site in July.

‘In West Africa, our non-operated assets continue to perform well,’ Tullow Oil CEO Paul McDade said. ‘However, Ghana production has not met our expectations this year and we are working closely with our Joint Venture Partners to ensure that both fields perform to their potential.’

You can go long or short GSK and Tullow Oil with IG using derivatives like CFDs.

However, the UK-based oil and gas company still has a bright future ahead of it, according to analysts from JP Morgan and Jefferies International.

Even though the pair downgraded their target price for the stock to 249p and 168p respectively in November, both banks believe that its share price has a potential upside of between 20% and 77.8% based on it trading at 140p as of 16:00 GMT on Tuesday.

This information has been prepared by IG, a trading name of IG Markets Ltd and IG Markets South Africa Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.

Seize a share opportunity today

Go long or short on thousands of international stocks.

  • Increase your market exposure with leverage
  • Get spreads from just 0.1% on major global shares
  • Trade CFDs straight into order books with direct market access

Live prices on most popular markets

  • Forex
  • Shares
  • Indices

Prices above are subject to our website terms and agreements. Prices are indicative only

Plan your trading week

Get the week’s market-moving news sent directly to your inbox every Monday. The Week Ahead gives you a full calendar of upcoming economic events, as well as commentary from our expert analysts on the key markets to watch.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.